---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-120691"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:12:49.945378+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amylyx updates corporate presentation: Phase 3 LUCIDITY enrollment complete, Phase 2 PREVENT analysis added

## Summary
- Completed enrollment in Phase 3 LUCIDITY trial.
- Added exploratory analysis of Phase 2 PREVENT study from ENDO 2025.
- Completed enrollment for Cohort 2 of Phase 1 LUMINA trial.

## SEC filing metadata
- accession: 0001193125-26-120691
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526120691/0001193125-26-120691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526120691/d49067d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-120691
- JSON: https://secwatch.observer/filing/0001193125-26-120691.json
- Plain text: https://secwatch.observer/filing/0001193125-26-120691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.